Media Zoom
SK bioscience-GSK’s Covid-19 vaccine meets Phase III trial’s coprimary goals
2022.05.02
SK bioscience and GlaxoSmithKline (GSK) have reported that their recombinant, protein-based, Covid-19 vaccine candidate, SKYCovione (GBP510/GSK adjuvant) met the coprimary goals in the Phase III clinical trial.
A self-assembled nanoparticle vaccine candidate, SKYCovione acts on the receptor-binding domain of the Spike protein of the SARS-CoV-2 virus.